Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study. - Lin, Min‐Hsi; Chu, Kuo‐An; Chen, Chiu‐Fan; Jiang, You‐Cheng; Hong, Wei‐Cheng; Hung, Ming‐Yen; Hsu, Chun‐Hsiang (Cancer Medicine, 2026)